Organon 

€16.64
625
-€0.38-2.23% Friday 15:30

統計

當日最高
-
當日最低
-
52週高點
-
52週低點
-
成交量
-
平均成交量
-
市值
0
本益比
-
股息殖利率
0.22%
股息
0.04

即將到來

股息

0.22%股息殖利率
Mar 26
€0.02
Dec 25
€0.02
Sep 25
€0.02
Jun 25
€0.02
Mar 25
€0.27
10年成長
不適用
5年成長
不適用
3年成長
-32.9%
1年成長
-68.96%

財報

30Apr預期
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
下一步
0.63
0.76
0.89
1.02
預期EPS
0.8305
實際EPS
不適用

財務

14.79%利潤率
有盈利
2019
2020
2021
2022
5.88B營收
869.68M淨利

分析師評級

7.34平均目標價
最高預估為 9.11。
來自過去6個月內的 3 則評分。這不是投資建議。
買入
0%
持有
33%
賣出
67%

其他人也在關注

此清單是根據在 Stock Events 上追蹤 7XP.XETRA 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1
Show more...
執行長
Ms. Carrie Smith Cox
員工
10000
國家
美國
ISIN
US68622V1061
WKN
000A3CPKP

上市

0 Comments

分享你的想法

FAQ

Organon 今天的股價是多少?
7XP.XETRA 目前價格為 €16.64 EUR,過去 24 小時下跌了 -2.23%。在圖表上更密切關注 Organon 股票的表現。
Organon 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Organon 的股票以代號 7XP.XETRA 進行交易。
Organon 去年的營收是多少?
Organon 去年的營收為 5.88BEUR。
Organon 去年的淨利是多少?
7XP.XETRA 去年的淨收益為 869.68MEUR。
Organon 會發放股息嗎?
是的,7XP.XETRA 的股息每 每季 發放一次。每股最新股息為 0.02 EUR。截至今日,股息殖利率(FWD)% 為 0.22%。
Organon 有多少名員工?
截至 April 20, 2026,公司共有 10,000 名員工。
Organon 位於哪個產業?
Organon從事於Other產業。
Organon 何時完成拆股?
Organon 最近沒有進行任何拆股。
Organon 的總部在哪裡?
Organon 的總部位於 美國 的 Jersey City。